STUDY OF HEPATOPROTECTIVE ACTIVITY OF A COMBINED FLAMIN/SILYMARIN MIXTURE FROM HERBAL ORIGIN IN EXPERIMENTAL CIRRHOSIS.

  • H. Gasparyan Scientific Technological Center of Organic and Pharmaceutical Chemistry
  • S. Buloyan Scientific Technological Center of Organic and Pharmaceutical Chemistry
  • L. Arshakyan Scientific Technological Center of Organic and Pharmaceutical Chemistry
Keywords: reddish immortelle (Helichrysum rubicundum), milk thistle (Silybum marianum), liver cirrhosis, Flamin/Silymarin mixture, histopathology.

Abstract

The aim of this study is to investigate Flamin/Silymarin as a new herbal combined hepatoprotective drug in experimental liver cirrhosis of white rats. Flamin was obtained from the flowers of the reddish immortelle (Helichrysum rubicundum (C. Koch.)), аnd Silymarin from the seeds of the milk thistle (Silybum marianum) growing in Armenia.

The histomorphological studies showed that in comparison with the two control groups under the influence of Flamin/Silymarin the destructive and dystrophic processes are much reduced in the liver parenchyma. The histostructure is mainly preserved: there are binucleated hepatocytes with nucleoli, the boundaries of the interlobular hepatic tracts are clearly formed. Compared with the group treated with Flamin, in animals treated with Flamin/Silymarin, there was a reduction of karyolysis and pyknosis in hepatocytes. Along with this, in some areas, there were small foci of fatty changes. It is assumed that with long-term therapy, the effectiveness of Flamin/Silymarin may be increased.

Consequently, further in-depth study of the mixture will lead to the identification and introduction of a new herbal hepatoprotective for the prevention and treatment of liver cirrhosis.

Author Biographies

H. Gasparyan , Scientific Technological Center of Organic and Pharmaceutical Chemistry

PhD, Head of laboratory of pharmacology and histopathology

S. Buloyan , Scientific Technological Center of Organic and Pharmaceutical Chemistry

PhD, researcher Laboratory of pharmacology and histopathology, Group leader of Histopathology

L. Arshakyan , Scientific Technological Center of Organic and Pharmaceutical Chemistry

PhD applicant, junior researcher, Laboratory of pharmacology and histopathology, Group leader of Cytology and Biochemistry research group

References

1. Beyoglu D., Idle R. J. Metabolomic insights into the mode of action of natural products in the treatment of liver disease // Biochemical Pharmacology. ­ 2020. – Vol. 180. – P. 114­171. DOI: 10.1016/j.bcp.2020.114171.
2. Czinner E., Hagymasi K., Blazovics A., Kery A., Szoke E., Lemberkovics E. In vitro antioxidant properties of Helichrysumarenarium (L.) Moench // JEthnopharmacol. ­ 2000. ­ Vol. 73, Is. 3. ­ P. 437–43. DOI: 10.1016/ S0378­8741(00)00304­4.
3. Mao Z, Gan C, Zhu J, Ma N, Wu L, Wang L, Wang X. Anti­atherosclerotic activities of flavonoids from the flowers of Helichrysum arenarium L. MOENCH through the pathway of anti­inflammation // Bioorg Med Chem Lett. – 2017.­ Vol. 27, No.12. – P. 2812­2817. DOI: 10.1016/j.bmcl.2017.04.076.
4. Goudzenko A.B., Tsourkan A.A. Elaboration of Approaches to The Standartiz Ofation Helichrysum Arenarium (1.) Moench in Plant Mixtures // Pharmacy & Pharmacology. – 2014. – Vol. 2, No.1(2). – P. 29­34. DOI: 10.19163/2307­9266­2014­2­1(2)­29­34.
5. Boyko N.N., Pisarev D.I., Zhilyakova E.T., Novikov O.O. Study and Modeling of Solvent Influence On Isosalipurposide Extraction from Helichrysi Arenarii Flowers // Pharmacy & Pharmacology. – 2018. –Vol. 6, No.4. – P. 340­350. (In Russ.) DOI: 10.19163/2307­9266­2018­6­4­340­350.
6. Pljevljakusic D., Bigovic D., Jankovic T., Jelacic S. and Savikin K. Sandy Eve­rlasting (Helichrysumarenarium (L.) Moench): Botanical, Chemical and Biological Properties // Front. Plant Sci. ­ 2018. ­ Vol. 9. ­ P. 1123. DOI: 10.3389/fpls.2018.01123.
7. Kramberger, K.; Jenko Praznikar, Z.; Baruca Arbeiter, A.; Petelin, A.; Bandelj, D.; Kenig, S. A Comparative Study of the Antioxidative Effects of Helichrysum italicum and Helichrysum arenarium Infusions // Antioxidants 2021. – Vol. 10. – P. 380. https://doi.org/10.3390/ antiox10030380.
8. Rigano D, Formisano C, Senatore F, Piacente S, Pagano E, Capasso R, Borrelli F, Izzo AA. Intestinal antispasmodic effects of Helichrysum italicum (Roth) Don ssp. italicum and chemical identification of the active ingredients // J Ethnopharmacol. ­ 2013. – Vol. 150, No.3. – P. 901­906. DOI: 10.1016/j.jep.2013.09.034.
9. Ananikyan G.S. Sravnitelnyj analiz antiradikalnoj aktivnosti flavonoidnyh komponentov socvetij bessmertnika krasnovatogo, plodov rastoropshi pyatnistoj i maklyury oranzhevoj // Him.zh.Armenii. ­ 2016. ­ T. 69, No 1­2. St. 143­150. http://chemistry.asjoa.am/id/eprint/7727.
10. Mahli, A., Koch, A., Czech, B. et al. Hepatoprotective effect of oral application of a silymarin extract in carbon tetrachloride­induced hepatotoxicity in rats // Clin Phytosci. – Vol. 1, No.5. ­ 2015. DOI: 10.1186/s40816­015­0006­z.
11. Rigano D., Formisano C., Senatore F., Piacente S., Pagano E., Capasso R., Borrelli F., Izzo A.A. Intestinal antispasmodic effects of Helichrysum italicum (Roth) Don ssp. italicum and chemical identification of the active ingredients // Journal of Ethnopharmacology. – Vol. 150, Is. 3. – 2013. – P. 901906. DOI: 10.1016/j.jep.2013.09.034.
12. Crocenzi F.A., Roma M.G. Silymarin as a new hepatoprotective agent in experimental cholestasis: New possibilities for an ancient medication // Curr. Med. Chem. ­ 2006. – Vol. 13. – P. 1055–1074. DOI: 10.2174/092986706776360950
13. Cacciapuoti F, Scognamiglio A, Palumbo R, Forte R, Cacciapuoti F. Silymarin in nonalcoholic fatty liver disease // World J Hepatol. – 2013. – Vol. 5, No.3. – P. 109­113. DOI: 10.4254/wjh.v5.i3.109.
14. Valentova K, Purchartova K, Rydlova L, et al. Sulfated Metabolites of Flavonolignans and 2,3Dehydroflavonolignans: Preparation and Properties // Int J Mol Sci. – 2018. – Vol. 19, No.8. – P.2349. DOI:10.3390/ijms19082349.
15. Linda M. McManus, Richard N. Mitchell, editors. Pathobiology of Human Disease // San Diego: Elsevier. – 2014. ­ P. 1770­1782. DOI: 10.1016/B978­012­386456­ 7.04202­7.
16. Beyoglu D, Idle JR. Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy // Metabolites. ­ 2020. – Vol.10, No.2. – P. 50. DOI:10.3390/metabo10020050
17. Mukhtar S, Xiaoxiong Z, Qamer S, Saad M, Mubarik MS, Mahmoud AH, Mohammed OB. Hepatoprotective activity of silymarin encapsulation against hepatic damage in albino rats // Saudi J Biol Sci. – 2021. – Vol. 28, No.1. – P. 717­723. DOI: 10.1016/j.sjbs.2020.10.063.
18. Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis // Gut. ­ 2006. ­ Suppl 6. – P. 1­12. DOI: 10.1136/gut.2006.099580.
19. Thomson MJ, Lok AS, Tapper EB. Optimizing medication management for patients with cirrhosis: Evidence­based strategies and their outcomes // Liver Int. – 2018. – Vol. 38, No.11. – P. 1882­1890. DOI: 10.1111/liv.13892.
20. Mnacakanyan V.A., Ananikyan G.S., Babahanyan M.A., Oganesyan L.E., Ovsepyan G.Yu., Sargisyan S.A. Sravnitelnoe izuchenie soderzhaniya zhirnogo masla i flavolignanov v semenah rastoropshi pyatnistoj /Silybummarianum (L.) Gaertn. / pochvennogo i gidroponicheskogo proishozhdeniya. Mezhdunarod. zhurn. prikladnyh i fundamentalnyh issledovanij, 2015, No.12, ch.8, s.1445­1447.
21. Korzhevskij D.E., Gilyarov A.V. Osnovy gistologicheskoj tehniki. Sankt­Peterburg. SpecLit, 2010. 95 s.
22. Hung GD, Li PC, Lee HS, Chang HM, Chien CT, Lee KL. Green tea extract supplementation ameliorates CCl4­induced hepatic oxidative stress, fibrosis, and acute­phase protein expression in rat // J Formos Med Assoc. – 2012. – Volo. 111, No.10. – P. 550­559. DOI: 10.1016/j.jfma.2011.06.026.
23. Wang T, Zhao LJ, Li P, Jiang H, Lu GC, Zhang WD, Li HL, Yuan BJ. Hepatoprotective effects and mechanisms of dehydrocavidine in rats with carbon tetrachloride­induced hepatic fibrosis // J Ethnopharmacol. – 2011. – Vol. 38, No.1. – P. 76­84. DOI: 10.1016/j.jep.2011.08.039.
24. Arshakyan L.M., Gasparyan H.G.,
Khachikyan M.H. Morfofunctional state of the liver tissue in the presence of experimental chirrhosis and in condition of treatment with flamin drug of herbal origin // FARMA. 2017. – No.14. ­ P. 52­56.
25. Hernandez­Gea V,Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol. – 2011. – Vol. 6. – P. 425­56. DOI: 10.1146/annurev­pathol011110­130246.
Published
2021-10-10
How to Cite
Gasparyan , H., S. Buloyan, and L. Arshakyan. 2021. “STUDY OF HEPATOPROTECTIVE ACTIVITY OF A COMBINED FLAMIN/SILYMARIN MIXTURE FROM HERBAL ORIGIN IN EXPERIMENTAL CIRRHOSIS. ”. EurasianUnionScientists, October, 16-21. https://bio-med.euroasia-science.ru/index.php/Euroasia/article/view/753.
Issue
EURASIAN UNION OF SCIENTISTS. SERIES: MEDICAL, BIOLOGICAL AND CHEMICAL SCIENCES. VOLUME 1 №9(90) (2021)
Section
Article

CC BY-ND

A work licensed in this way allows the following:

1. The freedom to use and perform the work: The licensee must be allowed to make any use, private or public, of the work.

2. The freedom to study the work and apply the information: The licensee must be allowed to examine the work and to use the knowledge gained from the work in any way. The license may not, for example, restrict "reverse engineering."

2. The freedom to redistribute copies: Copies may be sold, swapped or given away for free, in the same form as the original.